Single-cell analysis based dissection of clonality in myelofibrosis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
07 01 2020
Historique:
received: 01 07 2019
accepted: 28 11 2019
entrez: 9 1 2020
pubmed: 9 1 2020
medline: 21 4 2020
Statut: epublish

Résumé

Cancer development is an evolutionary genomic process with parallels to Darwinian selection. It requires acquisition of multiple somatic mutations that collectively cause a malignant phenotype and continuous clonal evolution is often linked to tumor progression. Here, we show the clonal evolution structure in 15 myelofibrosis (MF) patients while receiving treatment with JAK inhibitors (mean follow-up 3.9 years). Whole-exome sequencing at multiple time points reveal acquisition of somatic mutations and copy number aberrations over time. While JAK inhibition therapy does not seem to create a clear evolutionary bottleneck, we observe a more complex clonal architecture over time, and appearance of unrelated clones. Disease progression associates with increased genetic heterogeneity and gain of RAS/RTK pathway mutations. Clonal diversity results in clone-specific expansion within different myeloid cell lineages. Single-cell genotyping of circulating CD34 + progenitor cells allows the reconstruction of MF phylogeny demonstrating loss of heterozygosity and parallel evolution as recurrent events.

Identifiants

pubmed: 31911629
doi: 10.1038/s41467-019-13892-x
pii: 10.1038/s41467-019-13892-x
pmc: PMC6946829
doi:

Substances chimiques

Oncogene Protein p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

73

Références

Cancer Discov. 2019 Aug;9(8):1050-1063
pubmed: 31088841
Science. 2008 Nov 28;322(5906):1377-80
pubmed: 19039135
Leukemia. 2019 May;33(5):1113-1123
pubmed: 30568172
J Clin Oncol. 1984 Jan;2(1):8-15
pubmed: 6699660
Nature. 2015 Feb 12;518(7538):240-4
pubmed: 25409150
Nature. 2011 Sep 11;478(7367):64-9
pubmed: 21909114
Genome Med. 2018 Apr 25;10(1):33
pubmed: 29695279
Genome Biol. 2017 Sep 19;18(1):178
pubmed: 28927434
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Mayo Clin Proc. 2017 Aug;92(8):1283-1290
pubmed: 28778261
Genomics. 2015 Mar;105(3):159-67
pubmed: 25576655
Science. 2001 Aug 3;293(5531):876-80
pubmed: 11423618
PLoS Genet. 2015 Dec 02;11(12):e1005657
pubmed: 26630308
Blood. 2011 Dec 15;118(25):6601-9
pubmed: 21963603
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Nat Commun. 2017 Apr 21;8:15099
pubmed: 28429724
J Clin Invest. 2007 Sep;117(9):2562-9
pubmed: 17710227
Blood. 2007 Aug 15;110(4):1092-7
pubmed: 17488875
Nat Rev Cancer. 2006 Dec;6(12):924-35
pubmed: 17109012
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Cancer. 2017 Oct;17(10):605-619
pubmed: 28912577
J Clin Oncol. 2019 Feb 10;37(5):375-385
pubmed: 30403573
Am J Hematol. 2018 Mar;93(3):348-355
pubmed: 29164670
Blood. 2017 Mar 23;129(12):1607-1616
pubmed: 28159736
PLoS Comput Biol. 2014 Aug 07;10(8):e1003665
pubmed: 25102416
Nat Rev Genet. 2017 Apr;18(4):213-229
pubmed: 28190876
Genome Res. 2015 Oct;25(10):1499-507
pubmed: 26430160
Blood. 2019 Mar 7;133(10):1140-1151
pubmed: 30610028
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Nat Med. 2019 Mar;25(3):517-525
pubmed: 30664780
Blood. 2007 Jul 1;110(1):375-9
pubmed: 17363731
Blood. 2017 Aug 31;130(9):1125-1131
pubmed: 28674026
Nat Genet. 2015 Dec;47(12):1402-7
pubmed: 26551669
N Engl J Med. 2015 Feb 12;372(7):601-612
pubmed: 25671252
Genome Res. 2013 Dec;23(12):2115-25
pubmed: 24056532
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Science. 1976 Oct 1;194(4260):23-8
pubmed: 959840
N Engl J Med. 2018 Oct 11;379(15):1416-1430
pubmed: 30304655
Haematologica. 2019 May;104(5):e187-e190
pubmed: 30409794
Nature. 2019 Jan;565(7739):312-317
pubmed: 30602793
Ann Oncol. 2017 Dec 1;28(12):3076-3082
pubmed: 28950321
Nucleic Acids Res. 2013 Apr;41(7):e89
pubmed: 23471004
Blood. 2016 Dec 15;128(24):2863-2866
pubmed: 27784671
Annu Rev Med. 2015;66:129-43
pubmed: 25423595
Leukemia. 2018 Sep;32(9):1908-1919
pubmed: 29491455
Blood. 2014 Apr 3;123(14):2220-8
pubmed: 24478400
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
Haematologica. 2015 Aug;100(8):1051-7
pubmed: 26001790
Blood. 2014 Feb 27;123(9):1372-83
pubmed: 24398328
Blood. 2013 Mar 21;121(12):2186-98
pubmed: 23319568
Blood. 2015 Sep 24;126(13):1551-4
pubmed: 26228487
Cancer Discov. 2014 Sep;4(9):1088-101
pubmed: 24920063
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
F1000Res. 2016 Apr 19;5:
pubmed: 27134742
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187

Auteurs

Elena Mylonas (E)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Kenichi Yoshida (K)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Mareike Frick (M)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Kaja Hoyer (K)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Friederike Christen (F)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Jaspal Kaeda (J)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Matthias Obenaus (M)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Daniel Noerenberg (D)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Cornelius Hennch (C)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Willy Chan (W)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Yotaro Ochi (Y)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.

Yuichi Shiraishi (Y)

Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Yusuke Shiozawa (Y)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Thorsten Zenz (T)

Department of Medical Oncology and Hematology, University Hospital Zurich / University of Zurich, Zurich, Switzerland.

Christopher C Oakes (CC)

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

Birgit Sawitzki (B)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute for Medical Immunology, Berlin, Germany.

Michaela Schwarz (M)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Lars Bullinger (L)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Philipp le Coutre (P)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.

Matthew J J Rose-Zerilli (MJJ)

Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Seishi Ogawa (S)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
Department of Medicine, Centre for Haematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.

Frederik Damm (F)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany. frederik.damm@charite.de.
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. frederik.damm@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH